Low‐dose colchicine vs placebo
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
Findings
What do systematic reviews say?
4,918 questions · 5,537 findings · 1,803 reviews
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of findings table ‐ Intraperitoneal local anaesthetic vs control
Serious adverse events · people undergoing laparoscopic cholecystectomy.
It is very uncertain whether summary of findings table ‐ Intraperitoneal local anaesthetic changes serious adverse events compared with control (very low certainty).
1 finding from 1 review
- Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for… 2021 · Cochrane Headline outcomes onlyRR 1.07 [0.49, 2.34]13 studies · 988 participantsVery low
Oral hydroxychloroquine vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 3.9 [0.19, 78.46]1 study · 71 participantsModerate
Oral dehydroepiandrosterone vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 1.66]1 study · 381 participantsModerate
Oral chloroquine vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.33 [0.01, 7.45]1 study · 24 participantsLow
Oral ciclosporin vs azathioprine (AZA)
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.89 [0.48, 1.65]1 study · 89 participantsLow
Oral methotrexate vs oral chloroquine
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 1.73 [0.27, 11.07]1 study · 41 participantsLow
Oral methotrexate vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 12.05 [0.69, 211.36]1 study · 86 participantsModerate
Phentermine/topiramate vs placebo
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes onlyRR 0.85 [0.49, 1.48]1 study · 1305 participantsLow
Naltrexone/bupropion vs placebo
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes onlyRR 1.05 [0.96, 1.14]1 study · 8283 participantsModerate
Orlistat vs placebo
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes onlyRR 1.45 [1.1, 1.91]3 studies · 1476 participantsModerate
Intervention not reported
Serious adverse events · Heterosexual women
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
- Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes onlyRR 1 [0.81, 1.24]3 studies · 4958 participantsVery low
Intervention not reported
Serious adverse events · Heterosexual women
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
- Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes onlyRR 1.25 [0.87, 1.79]2 studies · 3069 participantsLow
Intervention not reported
Serious adverse events · heterosexual women
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
- Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes onlyRR 1.12 [0.94, 1.32]2 studies · 4588 participantsLow
Any dose of lacosamide vs placebo
Serious adverse events · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.535 studies · 2199 participantsModerate
Vitamin D vs placebo or no intervention
Serious adverse events · people with chronic liver diseases
1 finding from 1 review
- Vitamin D supplementation for chronic liver diseases in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Circumcision devices vs standard surgical techniques
Serious adverse events · adolescent and adult male circumcisions
1 finding from 1 review
- Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions 2021 · Cochrane Headline outcomes onlyno estimate extracted11 studies · 3472 participantsModerate
Degarelix vs standard androgen suppression therapy
Serious adverse events · hormone‐sensitive prostate cancer
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
1 finding from 1 review
- Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes onlyRR 0.8 [0.62, 1.05]9 studies · 2750 participantsLow
Adjuvant chemotherapy vs no chemotherapy
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
- Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes onlyRR 17.82 [2.43, 130.82]1 study · 219 participantsVery low
Adjuvant S‐1 vs gemcitabine
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
- Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 70 participantsVery low